Skip to main content

Table 3 Univariate analysis for predictors of pathologic complete response

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Variables

 

n

pCR n(%)

Non-pCR n(%)

Pvalue*

Ki-67

<30%

15

2 (13.3)

13 (86.7)

0.070

 

≥30%

18

8 (44.4)

10 (55.6)

 

Initial tumor size

≤2 cm

7

4 (57.1)

3 (42.9)

0.083

 

>2 cm

32

7 (21.9)

25 (78.1)

 

Initial clinical stage

II

22

5 (22.7)

17 (77.3)

0.482

 

III

17

6 (35.3)

11 (64.7)

 

Age, year

< median (43)

20

7 (35.0)

13 (65.0)

0.480

 

≥ median (43)

19

4 (21.1)

15 (78.9)

 

HR (10% of cut-off)

Negative

11

4 (36.4)

7 (63.6)

0.694

 

Positive

28

7 (25.0)

21 (75.0)

 
  1. HR, hormone receptor. *Chi-square or Fisher’s exact test.